Zentalis Pharmaceuticals, Inc.

ZNTL Healthcare Biotechnology

Zentalis Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $67.4 million. In the quarter to June 2026, EPS fell 59.5% and free cash flow fell 9.06%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

2.13 0.11 −4.91%
Market cap
$212.1M
P/E
0.0×
Fwd P/E
−1.4×
Dividend yield
—
F-score
n/a
Altman Z
−2.42
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Quick Ratio
4.64 6.01 6.73 7.55
Current Ratio
4.82 6.19 6.93 7.76
Net Debt/EBITDA
3.94 5.58 6.53 8.23
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.88 0.93 0.88 1.01
Capex/Depreciation
0.00 0.47 (0.47) 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow Yield
— — — —
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.52) (0.47) (0.43) (0.37)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.52) (0.47) (0.43) (0.37)
Cash per Share
2.45 3.01 3.42 3.89
Shareholders Equity per Share
2.01 2.60 3.01 3.51
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
2.01 2.60 3.01 3.51
Free Cash Flow
(37.24) (32.99) (30.81) (26.96)
Working Capital
143.65 182.86 216.63 251.13
Capital Expenditures
0.00 (0.03) 0.13 0.00
Net Current Asset Value
109.60 147.71 180.43 213.93
EV/EBIT
— — — —
Capex to Sales
0.00 0.00 0.00 0.00
Other line items
Average Payables
5.93 7.57 7.32 7.62
Average Assets
283.52 318.54 359.65 388.96
Average Common Equity
209.07 239.03 276.70 303.60

Fold the line items

Columns are period end dates